Pacira Biosciences, Inc. (PCRX)
36.48
0.00 (0.00%)
USD |
NASDAQ |
Nov 19, 16:00
Pacira Biosciences Free Cash Flow : 169.00M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | 169.00M |
| June 30, 2026 | 179.52M |
| March 31, 2026 | 132.71M |
| December 31, 2025 | 136.66M |
| September 30, 2025 | 124.20M |
| June 30, 2025 | 117.07M |
| March 31, 2025 | 159.40M |
| December 31, 2024 | 178.75M |
| September 30, 2024 | 193.52M |
| June 30, 2024 | 184.74M |
| March 31, 2024 | 173.19M |
| December 31, 2023 | 139.49M |
| September 30, 2023 | 130.25M |
| June 30, 2023 | 126.68M |
| March 31, 2023 | 104.65M |
| December 31, 2022 | 115.20M |
| September 30, 2022 | 92.70M |
| June 30, 2022 | 102.44M |
| March 31, 2022 | 103.95M |
| December 31, 2021 | 79.85M |
| September 30, 2021 | 98.06M |
| June 30, 2021 | 82.87M |
| March 31, 2021 | 38.76M |
| December 31, 2020 | 39.23M |
| September 30, 2020 | 28.38M |
| Date | Value |
|---|---|
| June 30, 2020 | 13.12M |
| March 31, 2020 | 58.36M |
| December 31, 2019 | 60.36M |
| September 30, 2019 | 57.93M |
| June 30, 2019 | 53.34M |
| March 31, 2019 | 43.71M |
| December 31, 2018 | 34.36M |
| September 30, 2018 | 27.23M |
| June 30, 2018 | 6.831M |
| March 31, 2018 | -5.744M |
| December 31, 2017 | -1.481M |
| September 30, 2017 | -0.869M |
| June 30, 2017 | 15.14M |
| March 31, 2017 | 15.31M |
| December 31, 2016 | 8.744M |
| September 30, 2016 | 4.188M |
| June 30, 2016 | -10.38M |
| March 31, 2016 | -13.70M |
| December 31, 2015 | -13.51M |
| September 30, 2015 | -15.39M |
| June 30, 2015 | -4.644M |
| March 31, 2015 | 4.569M |
| December 31, 2014 | 4.55M |
| September 30, 2014 | -11.21M |
| June 30, 2014 | -29.24M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Viatris, Inc. | 1.971B |
| Organon & Co. | 735.00M |
| ANI Pharmaceuticals, Inc. | 199.91M |
| Corcept Therapeutics, Inc. | 194.62M |
| Veru, Inc. | -26.04M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 50.07M |
| Cash from Investing (Quarterly) | 60.81M |
| Cash from Financing (Quarterly) | -69.77M |
| Free Cash Flow Per Share (Quarterly) | 1.138 |
| Free Cash Flow to Equity (Quarterly) | 118.28M |
| Free Cash Flow to Firm (Quarterly) | 49.30M |
| Free Cash Flow Yield | 11.61% |